We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
-22.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$402M
AUM Growth
-$164M
(-29%)
Cap. Flow
+$47.9M
Cap. Flow
% of AUM
11.9%
Top 10 Holdings %
Top 10 Hldgs %
62.89%
Holding
86
New
14
Increased
17
Reduced
23
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$55.3M |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$43M |
| 3 |
TG Therapeutics
TGTX
|
+$21.3M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$20.9M |
| 5 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$21.9M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$18.3M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$16M |
| 4 |
The Ensign Group
ENSG
|
+$14M |
| 5 |
Sanofi
SNY
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.24% |
| 2 | Miscellaneous | 5.59% |
| 3 | Communication Services | 2.07% |
| 4 | Financials | 0.11% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Aquestive Therapeutics
AQST
$630M
| $657K | 0.16% |
300,000
-50,000
| -14% | -$190K |
|
|
AMRN
52
PUT
Amarin Corp
AMRN
$295M
| $600K | 0.15% |
+7,500
| New | +$2.49M |
|
|
IGMS
53
DELISTED
IGM Biosciences
IGMS
| $549K | 0.14% |
9,770
-54,830
| -85% | -$2.4M |
|
54
MacroGenics
MGNX
$263M
| $535K | 0.13% |
91,998
-25,000
| -21% | -$227K |
|
55
Puma Biotechnology
PBYI
$468M
| $492K | 0.12% |
+58,251
| New | +$566K |
|
|
EIGR
56
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $474K | 0.12% |
2,324
| – | – |
|
|
BDSI
57
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $465K | 0.12% |
122,702
-212,783
| -63% | -$1.05M |
|
58
eHealth
EHTH
$38.4M
| $444K | 0.11% |
3,153
-28,500
| -90% | -$3.27M |
|
|
AL
59
PUT
DELISTED
Air Lease Corp
AL
| $443K | 0.11% |
+20,000
| New | +$760K |
|
|
PFNX
60
DELISTED
Pfenex Inc.
PFNX
| $408K | 0.1% |
46,293
| – | – |
|
|
ZGNX
61
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $136K | 0.03% |
+5,500
| New | +$200K |
|
62
argenx
ARGX
$64B
| – | – |
-37,204
| Closed | -$5.97M |
|
|
BLUE
63
DELISTED
bluebird bio
BLUE
| – | – |
-5,666
| Closed | -$6.44M |
|
64
Centene
CNC
$32B
| – | – |
-40,000
| Closed | -$2.51M |
|
65
Collegium Pharmaceutical
COLL
$786M
| – | – |
-111,361
| Closed | -$2.29M |
|
66
CareTrust REIT
CTRE
$9.22B
| – | – |
-107,464
| Closed | -$2.24M |
|
67
Elevance Health
ELV
$85.5B
| – | – |
-10,000
| Closed | -$3.02M |
|
68
Guardant Health
GH
$21.7B
| – | – |
-64,720
| Closed | -$5.06M |
|
69
Humana
HUM
$46.3B
| – | – |
-5,009
| Closed | -$1.84M |
|
70
Illumina
ILMN
$32.6B
| – | – |
-18,247
| Closed | -$5.89M |
|
|
LTC
71
LTC Properties
LTC
$2.19B
| – | – |
-59,327
| Closed | -$2.66M |
|
72
Natera
NTRA
$47B
| – | – |
-157,081
| Closed | -$5.29M |
|
73
Omega Healthcare
OHI
$13.9B
| – | – |
-71,500
| Closed | -$3.03M |
|
|
OPTN
74
DELISTED
OptiNose
OPTN
| – | – |
-7,000
| Closed | -$968K |
|
75
Qiagen
QGEN
$8.9B
| – | – |
-129,199
| Closed | -$4.63M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q1 2020 Portfolio in Review
As of Q1 2020, Eversept Partners held 86 positions worth $402M, down 29% from $566M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Eversept Partners deployed $47.9M of net new capital in Q1 2020, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was HCA Healthcare: 101,000 shares worth $9.07M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Communication Services.
On the sell side, the largest reduction was GSK, an estimated $21.9M trimmed.
- Eversept Partners's largest Q1 2020 buy was HCA Healthcare: 101,000 shares worth $9.07M.
- Eversept Partners added most to Zogenix, Inc. in Q1 2020, an estimated $55.3M increase.
- Eversept Partners's biggest Q1 2020 reduction was GSK, cutting an estimated $21.9M.
- Eversept Partners fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $18.3M.
- Eversept Partners's ten largest holdings make up 63% of its $402M portfolio in Q1 2020.
- Eversept Partners opened 14 new positions and closed 25 in Q1 2020.
- Eversept Partners's portfolio value fell 29% quarter-over-quarter to $402M.
Based on Eversept Partners's 13F filing for Q1 2020, filed 13 May 2020.